Feasibility of reducing rabies immunoglobulin dosage for passive immunization against rabies : Results of in vitro and in vivo studies

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 9, 2013, Pages 1914-1917

  Madhusudana, Shampur Narayan ^a   Ashwin, Belludi Yajaman ^a   Sudarshan, Sampada ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Equine rabies immunoglobulin; Human rabies immunoglobulin; Passive immunization; Post exposure prophylaxis; Rabies

Indexed keywords

EQUINE RABIES IMMUNOGLOBULIN; IMMUNOGLOBULIN; RABIES IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HORSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MORTALITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; RABIES; RABIES VIRUS; SURVIVAL RATE; VIRUS IDENTIFICATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TITRATION;

EQUINE RABIES IMMUNOGLOBULIN; HUMAN RABIES IMMUNOGLOBULIN; PASSIVE IMMUNIZATION; POST-EXPOSURE PROPHYLAXIS; RABIES;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CRICETINAE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; MICE; POST-EXPOSURE PROPHYLAXIS; RABIES; SURVIVAL ANALYSIS;

EID: 84884626033     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25431     Document Type: Article

References (20)

1. World Health Organzation. Expert consultation on rabies. First report. Tech Rep Ser 931, Geneva, WHO, 2005.
2. Habel K. Seropprophylaxis in experimental rabies. Public Health Rep 1945; 60:545-60; PMID:19316026; http://dx.doi.org/10.2307/4585257
3. Koprowski H, Van Der Scheer J, Black J. Use of hyperimmune anti-rabies serum concentrates in experimental rabies. Am J Med 1950; 8:412-20; PMID:15410721; http://dx.doi.org/10.1016/0002-9343(50)90224-5
4. Atanasiu P, Bahmanyar M, Balatazard M. Rabies neutralizing antibody response to different schedules of serum and vaccine inoculation in non exposed persons. Bull World Health Organ 1955; 13:747-51; PMID:13284556
5. World Health Organization. Expert committee on rabies, 6th report. Tech Rep Ser 523, Geneva, WHO, 1973.
6. World Health Organization. Expert committee on rabies 7th report. Tech Rep Ser 709 WHO, Geneva, 1984.
7. World Health Organization. Expert committee on rabies 8th report. Tech Rep Ser 824 Geneva, WHO, 1992.
8. Quiambao BP, Dy-Tioco HZ, Dizon RM, Crisostomo ME, Teuwen DE. Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: oneyear follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines. Vaccine 2009; 27:7162-6; PMID:19925947; http://dx.doi.org/10. 1016/j.vaccine.2009.09.036
9. Müller T, Dietzschold B, Ertl H, Fooks AR, Freuling C, Fehlner-Gardiner C, et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 2009; 3:e542; PMID:19888334; http://dx.doi.org/10.1371/journal.pntd.0000542
10. Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008; 26:5922-7; PMID:18804136; http://dx.doi.org/10.1016/j.vaccine.2008.08.050
11. Gogtay N, Thatte U, Kshirsagar N, Leav B, Molrine D, Cheslock P, et al.; SII RMab author group. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine 2012; 30:7315-20; PMID:23010601; http://dx.doi.org/10.1016/j.vaccine. 2012.09.027
12. Muhamuda K, Madhusudana SN, Ravi V. Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies. Hum Vaccin 2007; 3:192-5; PMID:17637573; http://dx.doi.org/10.4161/hv.3.5.4386
13. Hemachudha T, Mitrabhakdi E, Wilde H, Vejabhuti A, Siripataravanit S, Kingnate D. Additional reports of failure to respond to treatment after rabies exposure in Thailand. Clin Infect Dis 1999; 28:143-4; PMID:10028088; http://dx.doi.org/10.1086/517179
14. Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Ashwath Narayana DH, Abdul Rahman S, et al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 2007; 11:29-35; PMID:16678463; http://dx.doi.org/10.1016/j.ijid.2005.10.007
15. Fang LX, Ping F, Ping Y, Hui BG, Yan YX. Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis. [d]. Vaccine 2010; 28:6847-51; PMID:20723628; http://dx.doi.org/10.1016/j.vaccine.2010.08.034
16. Wilde H, Chutivongse S. Equine rabies immune globulin: a product with an undeserved poor reputation. Am J Trop Med Hyg 1990; 42:175-8; PMID:2316787
17. Archer BG, Dierks RE. Effects of homologous or heterologous antiserum on neutralizing-antibody response to rabies vaccine. Bull World Health Organ 1968; 39:407-17; PMID:5303907
18. World Health Organization. Human and dog rabies prevention and control. Report of the WHO/Bill Gates Foundation Consultation. 7-9 October 2009, Annecy, France WHO/HTM/NTD/NZD/2010.1.
19. Fekadu M, Shaddock JH, Baer GM. Excretion of rabies virus in the saliva of dogs. J Infect Dis 1982; 145:715-9; PMID:7077094; http://dx.doi.org/10.1093/ infdis/145.2.715
20. Vaughn JB Jr., Gerhardt P, Newell KW. Excretion of street rabies virus in the saliva of dogs. JAMA 1965; 193:363-8; PMID:14313891; http://dx.doi.org/10. 1001/jama.1965.03090050039010